Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kirkwood, J. M.
Right arrow Articles by Blum, R. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kirkwood, J. M.
Right arrow Articles by Blum, R. H.

Journal of Clinical Oncology, Vol 14, 7-17, Copyright © 1996 by American Society of Clinical Oncology

ARTICLES

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684

JM Kirkwood, MH Strawderman, MS Ernstoff, TJ Smith, EC Borden and RH Blum
Division of Medical Oncology, University of Pittsburgh, PA 15213-2582, USA.

PURPOSE: Interferon alfa-2b (IFN alpha-2b) exhibits antitumor activity in metastatic melanoma and on this basis has been evaluated as an adjuvant therapy following surgery for deep primary (T4) or regionally metastatic (N1) melanoma. METHODS: A randomized controlled study of IFN alpha-2b (Schering-Plough, Kenilworth, NJ) administered at maximum- tolerated doses of 20 MU/m2/d intravenously (i.v.) for 1 month and 10 MU/m2 three times per week subcutaneously (SC) for 48 weeks versus observation, was conducted by the Eastern Cooperative Oncology Group (ECOG) in 287 patients. RESULTS: A significant prolongation of relapse- free survival (P = .0023, one-sided) and prolongation of overall survival (P = .0237, one-sided) was observed with IFN alpha-2b therapy in this trial, which is now mature with a median follow-up time of 6.9 years. The impact of treatment on relapse rate is most pronounced early during the treatment interval. The overall benefit of treatment in this trial was analyzed stratified by tumor burden and the presence or absence of microscopic nonpalpable and palpable regional lymph node metastasis. The benefit of therapy with IFN alpha-2b was greatest among node-positive strata. Toxicity of IFN alpha-2b required dose modification in the majority of patients, but treatment at > or = 80% of the scheduled dose was feasible in the majority of patients through the IV phase of treatment, and for more than 3 months of SC maintenance therapy. Discontinuation of treatment due to toxicity was infrequent after the fourth month of therapy. CONCLUSION: IFN alpha-2b prolongs the relapse-free interval and overall survival of high-risk resected melanoma patients. The increment in median disease-free survival (from 1 to 1.7 years) and overall survival (from 2.8 to 3.8 years) that results from this therapy is associated with a 42% improvement in the fraction of patients who are continuously disease-free after treatment with IFN (from 26% to 37%) in comparison to observation. IFN alpha-2b is the first agent to show a significant benefit in relapse-free and overall survival of high-risk melanoma patients in a randomized controlled trial.


This article has been cited by other articles:


Home page
 J. Immunol.Home page
G. Gerlini, G. Mariotti, A. Chiarugi, P. Di Gennaro, R. Caporale, A. Parenti, L. Cavone, A. Tun-Kyi, F. Prignano, R. Saccardi, et al.
Induction of CD83+CD14+ Nondendritic Antigen-Presenting Cells by Exposure of Monocytes to IFN-{alpha}
J. Immunol., September 1, 2008; 181(5): 2999 - 3008.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. John, M. A. Black, T. T. Toro, D. Leader, C. A. Gedye, I. D. Davis, P. J. Guilford, and J. S. Cebon
Predicting Clinical Outcome through Molecular Profiling in Stage III Melanoma
Clin. Cancer Res., August 15, 2008; 14(16): 5173 - 5180.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. M. Kirkwood, A. A. Tarhini, M. C. Panelli, S. J. Moschos, H. M. Zarour, L. H. Butterfield, and H. J. Gogas
Next Generation of Immunotherapy for Melanoma
J. Clin. Oncol., July 10, 2008; 26(20): 3445 - 3455.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
K. Y. Bilimoria, C. M. Balch, D. J. Bentrem, M. S. Talamonti, C. Y. Ko, J. R. Lange, D. P. Winchester, and J. D. Wayne
Complete Lymph Node Dissection for Sentinel Node-Positive Melanoma: Assessment of Practice Patterns in the United States
Ann. Surg. Oncol., June 1, 2008; 15(6): 1566 - 1576.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C. Garbe, P. Radny, R. Linse, R. Dummer, R. Gutzmer, J. Ulrich, R. Stadler, M. Weichenthal, TK. Eigentler, U. Ellwanger, et al.
Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis
Ann. Onc., June 1, 2008; 19(6): 1195 - 1201.
[Abstract] [Full Text] [PDF]

Home page
 Arch DermatolHome page
F. Grange, F. Vitry, F. Granel-Brocard, D. Lipsker, F. Aubin, G. Hedelin, S. Dalac, F. Truchetet, C. Michel, M.-L. Batard, et al.
Variations in Management of Stage I to Stage III Cutaneous Melanoma: A Population-Based Study of Clinical Practices in France
Arch Dermatol, May 1, 2008; 144(5): 629 - 636.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. M. Zimmerer, A. M. Lehman, A. S. Ruppert, C. W. Noble, T. Olencki, M. J. Walker, K. Kendra, and W. E. Carson III
IFN-{alpha}-2b-Induced Signal Transduction and Gene Regulation in Patient Peripheral Blood Mononuclear Cells Is Not Enhanced by a Dose Increase from 5 to 10 Megaunits/m2
Clin. Cancer Res., March 1, 2008; 14(5): 1438 - 1445.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. L. Slingluff Jr., G. R. Petroni, K. A. Chianese-Bullock, M. E. Smolkin, S. Hibbitts, C. Murphy, N. Johansen, W. W. Grosh, G. V. Yamshchikov, P. Y. Neese, et al.
Immunologic and Clinical Outcomes of a Randomized Phase II Trial of Two Multipeptide Vaccines for Melanoma in the Adjuvant Setting
Clin. Cancer Res., November 1, 2007; 13(21): 6386 - 6395.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
J. Kaae, J. Wohlfahrt, H. A. Boyd, H. C. Wulf, R. J. Biggar, and M. Melbye
The Impact of Autoimmune Diseases on the Incidence and Prognosis of Cutaneous Malignant Melanoma
Cancer Epidemiol. Biomarkers Prev., September 1, 2007; 16(9): 1840 - 1844.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. B. Lesinski, J. Trefry, M. Brasdovich, S. V. Kondadasula, K. Sackey, J. M. Zimmerer, A. R. Chaudhury, L. Yu, X. Zhang, T. R. Crespin, et al.
Melanoma Cells Exhibit Variable Signal Transducer and Activator of Transcription 1 Phosphorylation and a Reduced Response to IFN-{alpha} Compared with Immune Effector Cells
Clin. Cancer Res., September 1, 2007; 13(17): 5010 - 5019.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. N. Cormier, Y. Xing, M. Ding, S. B. Cantor, K. J. Salter, J. E. Lee, P. F. Mansfield, J. E. Gershenwald, and M. I. Ross
Cost Effectiveness of Adjuvant Interferon in Node-Positive Melanoma
J. Clin. Oncol., June 10, 2007; 25(17): 2442 - 2448.
[Abstract] [Full Text] [PDF]

Home page
 Arch DermatolHome page
K. Y. Tsai
Systemic Adjuvant Therapy for Patients With High-Risk Melanoma
Arch Dermatol, June 1, 2007; 143(6): 779 - 782.
[Full Text] [PDF]

Home page
 JCOHome page
M. S. Mitchell, J. Abrams, J. A. Thompson, M. Kashani-Sabet, R. C. DeConti, W.-J. Hwu, M. B. Atkins, E. Whitman, M. S. Ernstoff, F. G. Haluska, et al.
Randomized Trial of an Allogeneic Melanoma Lysate Vaccine With Low-Dose Interferon Alfa-2b Compared With High-Dose Interferon Alfa-2b for Resected Stage III Cutaneous Melanoma
J. Clin. Oncol., May 20, 2007; 25(15): 2078 - 2085.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. M. Zimmerer, G. B. Lesinski, S. V. Kondadasula, V. I. Karpa, A. Lehman, A. RayChaudhury, B. Becknell, and W. E. Carson III
IFN-{alpha}-Induced Signal Transduction, Gene Expression, and Antitumor Activity of Immune Effector Cells Are Negatively Regulated by Suppressor of Cytokine Signaling Proteins
J. Immunol., April 15, 2007; 178(8): 4832 - 4845.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. Wang, H. D. Edington, U. N.M. Rao, D. M. Jukic, S. R. Land, S. Ferrone, and J. M. Kirkwood
Modulation of Signal Transducers and Activators of Transcription 1 and 3 Signaling in Melanoma by High-Dose IFN{alpha}2b
Clin. Cancer Res., March 1, 2007; 13(5): 1523 - 1531.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. A. Lynch, J. Etchin, T. E. Battle, and D. A. Frank
A Small-Molecule Enhancer of Signal Transducer and Activator of Transcription 1 Transcriptional Activity Accentuates the Antiproliferative Effects of IFN-{gamma} in Human Cancer Cells
Cancer Res., February 1, 2007; 67(3): 1254 - 1261.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J. F. Thompson, F. S. Hodi, and A. Zembowicz
Case 2-2007 -- A 49-Year-Old Woman with a Pigmented Lesion on the Arm
N. Engl. J. Med., January 18, 2007; 356(3): 285 - 292.
[Full Text] [PDF]

Home page
 Genes Dev.Home page
L. Chin, L. A. Garraway, and D. E. Fisher
Malignant melanoma: genetics and therapeutics in the genomic era.
Genes & Dev., August 15, 2006; 20(16): 2149 - 2182.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. J. Moschos, H. D. Edington, S. R. Land, U. N. Rao, D. Jukic, J. Shipe-Spotloe, and J. M. Kirkwood
Neoadjuvant Treatment of Regional Stage IIIB Melanoma With High-Dose Interferon Alfa-2b Induces Objective Tumor Regression in Association With Modulation of Tumor Infiltrating Host Cellular Immune Responses
J. Clin. Oncol., July 1, 2006; 24(19): 3164 - 3171.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
S. Kettlewell, C. Moyes, C. Bray, D. Soutar, A. MacKay, D. Byrne, T. Shoaib, B. Majumder, and R. MacKie
Value of sentinel node status as a prognostic factor in melanoma: prospective observational study
BMJ, June 17, 2006; 332(7555): 1423.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
T. Z. Belhocine, A. M. Scott, E. Even-Sapir, J.-L. Urbain, and R. Essner
Role of Nuclear Medicine in the Management of Cutaneous Malignant Melanoma
J. Nucl. Med., June 1, 2006; 47(6): 957 - 967.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. A. Tarhini, J. Shipe-Spotloe, M. DeMark, S. S. Agarwala, and J. M. Kirkwood
Response to "Helping Melanoma Patients Decide Whether to Choose Adjuvant High-Dose Interferon-{alpha}2b".
Oncologist, May 1, 2006; 11(5): 538 - 539.
[Full Text] [PDF]

Home page
 Br. J. Ophthalmol.Home page
J Garcia-Arumi, M Morral Palau, M Montolio Gil, H Blasco Garrido, L Sararols Ramsay, and A Segura Garcia
Bilateral juxtapapillary choroidal neovascularisation associated with interferon alfa treatment of a metastatic cutaneous melanoma.
Br. J. Ophthalmol., April 1, 2006; 90(4): 516 - 518.
[Full Text] [PDF]

Home page
 NEJMHome page
H. Gogas, J. Ioannovich, U. Dafni, C. Stavropoulou-Giokas, K. Frangia, D. Tsoutsos, P. Panagiotou, A. Polyzos, O. Papadopoulos, A. Stratigos, et al.
Prognostic Significance of Autoimmunity during Treatment of Melanoma with Interferon
N. Engl. J. Med., February 16, 2006; 354(7): 709 - 718.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
J. Vaquerano, W. G. Kraybill, D. L. Driscoll, R. Cheney, and J. M. Kane III
American Joint Committee on Cancer Clinical Stage as a Selection Criterion for Sentinel Lymph Node Biopsy in Thin Melanoma
Ann. Surg. Oncol., February 1, 2006; 13(2): 198 - 204.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. M. Kirkwood
Building Upon the Standard of Care in Adjuvant Therapy of High-Risk Melanoma
J. Clin. Oncol., December 1, 2005; 23(34): 8559 - 8563.
[Full Text] [PDF]

Home page
 JCOHome page
E. Richtig, H. P. Soyer, M. Posch, U. Mossbacher, P. Bauer, L. Teban, G. Svolba, I. H. Wolf, P. Fritsch, B. Zelger, et al.
Prospective, Randomized, Multicenter, Double-Blind Placebo-Controlled Trial Comparing Adjuvant Interferon Alfa and Isotretinoin With Interferon Alfa Alone in Stage IIA and IIB Melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group
J. Clin. Oncol., December 1, 2005; 23(34): 8655 - 8663.
[Abstract] [Full Text] [PDF]

Home page
 Arch SurgHome page
N. Nathansohn, J. Schachter, and H. Gutman
Patterns of Recurrence in Patients With Melanoma After Radical Lymph Node Dissection
Arch Surg, December 1, 2005; 140(12): 1172 - 1177.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Romanini, G. Manca, D. Pellegrino, R. Murr, S. Sarti, F. Bianchi, A. AlSharif, C. Orlandini, V. Zucchi, M. Castagna, et al.
Molecular staging of the sentinel lymph node in melanoma patients: correlation with clinical outcome
Ann. Onc., November 1, 2005; 16(11): 1832 - 1840.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. P. Linette, D. Zhang, F. S. Hodi, E. P. Jonasch, S. Longerich, C. P. Stowell, I. J. Webb, H. Daley, R. J. Soiffer, A. M. Cheung, et al.
Immunization Using Autologous Dendritic Cells Pulsed with the Melanoma-Associated Antigen gp100-Derived G280-9V Peptide Elicits CD8+ Immunity
Clin. Cancer Res., November 1, 2005; 11(21): 7692 - 7699.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
K. E. Hurley and P. B. Chapman
Helping Melanoma Patients Decide Whether to Choose Adjuvant High-Dose Interferon-{alpha}2b
Oncologist, October 1, 2005; 10(9): 739 - 742.
[Abstract] [Full Text] [PDF]

Home page
 Integr Cancer TherHome page
D. Nathan
Medical Oncology
Integr Cancer Ther, September 1, 2005; 4(3): 251 - 253.
[PDF]

Home page
 JCOHome page
J. C. Kang, L. A. Wanek, R. Essner, M. B. Faries, L. J. Foshag, and D. L. Morton
Sentinel Lymphadenectomy Does Not Increase the Incidence of In-Transit Metastases in Primary Melanoma
J. Clin. Oncol., July 20, 2005; 23(21): 4764 - 4770.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
K. A. Skinner
Antitumor Vaccines: Of Mice and Men?
Ann. Surg. Oncol., July 1, 2005; 12(7): 511 - 512.
[Full Text] [PDF]

Home page
 PediatricsHome page
A. Ferrari, A. Bono, M. Baldi, P. Collini, M. Casanova, E. Pennacchioli, M. Terenziani, I. Marcon, M. Santinami, and C. Bartoli
Does Melanoma Behave Differently in Younger Children Than in Adults? A Retrospective Study of 33 Cases of Childhood Melanoma From a Single Institution
Pediatrics, March 1, 2005; 115(3): 649 - 654.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. H. Lee, H. Torisu-Itakara, A. J. Cochran, A. Kadison, Y. Huynh, D. L. Morton, and R. Essner
Quantitative Analysis of Melanoma-Induced Cytokine-Mediated Immunosuppression in Melanoma Sentinel Nodes
Clin. Cancer Res., January 1, 2005; 11(1): 107 - 112.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Ophthalmol.Home page
P N Tulley, M Neale, D Jackson, J S Chana, R Grover, I Cree, A O Grobbelaar, and G D Wilson
The relation between c-myc expression and interferon sensitivity in uveal melanoma
Br. J. Ophthalmol., December 1, 2004; 88(12): 1563 - 1567.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
E. C. Hsueh, E. Famatiga, S. Shu, X. Ye, and D. L. Morton
Peripheral Blood CD4+ T-Cell Response Before Postoperative Active Immunotherapy Correlates with Clinical Outcome in Metastatic Melanoma
Ann. Surg. Oncol., October 1, 2004; 11(10): 892 - 899.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
S.-F. Wong, J. G Jakowatz, and R. Taheri
Management of Hypertriglyceridemia in Patients Receiving Interferon for Malignant Melanoma
Ann. Pharmacother., October 1, 2004; 38(10): 1655 - 1659.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
H. Tsao, M. B. Atkins, and A. J. Sober
Management of Cutaneous Melanoma
N. Engl. J. Med., September 2, 2004; 351(10): 998 - 1012.
[Full Text] [PDF]

Home page
 Arch SurgHome page
D. E. Hemmings, D. S. Johnson, G. T. Tominaga, and J. H. Wong
Cutaneous Melanoma in a Multiethnic Population: Is This a Different Disease?
Arch Surg, September 1, 2004; 139(9): 968 - 973.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
S. E. Finkelstein, D. M. Heimann, C. A. Klebanoff, P. A. Antony, L. Gattinoni, C. S. Hinrichs, L. N. Hwang, D. C. Palmer, P. J. Spiess, D. R. Surman, et al.
Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer
J. Leukoc. Biol., August 1, 2004; 76(2): 333 - 337.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
G. B. Lesinski, B. Badgwell, J. Zimmerer, T. Crespin, Y. Hu, G. Abood, and W. E. Carson III
IL-12 Pretreatments Enhance IFN-{alpha}-Induced Janus Kinase-STAT Signaling and Potentiate the Antitumor Effects of IFN-{alpha} in a Murine Model of Malignant Melanoma
J. Immunol., June 15, 2004; 172(12): 7368 - 7376.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. M. Kirkwood, J. Manola, J. Ibrahim, V. Sondak, M. S. Ernstoff, and U. Rao
A Pooled Analysis of Eastern Cooperative Oncology Group and Intergroup Trials of Adjuvant High-Dose Interferon for Melanoma
Clin. Cancer Res., March 1, 2004; 10(5): 1670 - 1677.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
D. S. Reintgen, J. W. Jakub, S. Pendas, G. Swor, R. Giuliano, and S. Shivers
The Staging of Malignant Melanoma and the Florida Melanoma Trial
Ann. Surg. Oncol., March 1, 2004; 11(3_suppl): 186S - 191S.
[Abstract] [Full Text] [PDF]

Home page
 Arch DermatolHome page
M. H. Kanzler
Sentinel Lymph Node Biopsy in Patients With Thin Melanoma
Arch Dermatol, February 1, 2004; 140(2): 237 - 238.
[Full Text] [PDF]

Home page
 JCOHome page
L. M. Schuchter
Adjuvant Interferon Therapy for Melanoma: High-Dose, Low-Dose, No Dose, Which Dose?
J. Clin. Oncol., January 1, 2004; 22(1): 7 - 10.
[Full Text] [PDF]

Home page
 JCOHome page
B.W. Hancock, K. Wheatley, S. Harris, N. Ives, G. Harrison, J.M. Horsman, M.R. Middleton, N. Thatcher, P.C. Lorigan, J.R. Marsden, et al.
Adjuvant Interferon in High-Risk Melanoma: The AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research Randomized Study of Adjuvant Low-Dose Extended-Duration Interferon Alfa-2a in High-Risk Resected Malignant Melanoma
J. Clin. Oncol., January 1, 2004; 22(1): 53 - 61.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. J. Moschos, J. M. Kirkwood, and P. A. Konstantinopoulos
Present Status and Future Prospects for Adjuvant Therapy of Melanoma: Time to Build upon the Foundation of High-dose Interferon Alfa-2b
J. Clin. Oncol., January 1, 2004; 22(1): 11 - 14.
[Full Text] [PDF]

Home page
 Arch DermatolHome page
S. M. Swetter, P. M. Ecker, D. L. Johnson, and J. D. Harvell
Primary Dermal Melanoma: A Distinct Subtype of Melanoma
Arch Dermatol, January 1, 2004; 140(1): 99 - 103.
[Abstract] [Full Text] [PDF]

Home page
 Arch DermatolHome page
N. Ready and M. A. Weinstock
Adjuvant High-Dose Interferon Therapy for High-Risk Melanoma
Arch Dermatol, December 1, 2003; 139(12): 1635 - 1637.
[Full Text] [PDF]

Home page
 Arch OphthalmolHome page
B. Esmaeli, D. Reifler, V. G. Prieto, M. Amir Ahmadi, L. Hidaji, E. Delpassand, and M. I. Ross
Conjunctival Melanoma With a Positive Sentinel Lymph Node
Arch Ophthalmol, December 1, 2003; 121(12): 1779 - 1783.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. P. Cuadrado, M. d. C. Moreno Koch, C. F. Perez, L. M. Castejon Castan, C. P. Villalobos, M. J. Gonzalez Mateos, and C. L. Olmos
Immunomodulation in Established Murine Tumors: Response and Survival Rate Enhancement by Blood Leukocyte-Augmenting Substance 236 (Cl-), a Novel Synthetic Compound
Clin. Cancer Res., November 15, 2003; 9(15): 5776 - 5785.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
I. Astsaturov, T. Petrella, E. U. Bagriacik, M. de Benedette, R. Uger, G. Lumber, N. Berinstein, I. Elias, N. Iscoe, C. Hammond, et al.
Amplification of Virus-Induced Antimelanoma T-Cell Reactivity by High-Dose Interferon-{alpha}2b: Implications for Cancer Vaccines
Clin. Cancer Res., October 1, 2003; 9(12): 4347 - 4355.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. S. Sabel and V. K. Sondak
Pros and Cons of Adjuvant Interferon in the Treatment of Melanoma
Oncologist, October 1, 2003; 8(5): 451 - 458.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Hauschild, M. Weichenthal, B.-R. Balda, J. C. Becker, H. H. Wolff, W. Tilgen, K.-W. Schulte, J. Ring, D. Schadendorf, S. Lischner, et al.
Prospective Randomized Trial of Interferon Alfa-2b and Interleukin-2 as Adjuvant Treatment for Resected Intermediate- and High-Risk Primary Melanoma Without Clinically Detectable Node Metastasis
J. Clin. Oncol., August 1, 2003; 21(15): 2883 - 2888.
[Abstract] [Full Text] [PDF]

Home page